These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22398057)

  • 1. Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab.
    Ogawa K; Matsumoto T; Esaki M; Torisu T; Iida M
    J Crohns Colitis; 2012 Jun; 6(5):529-35. PubMed ID: 22398057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.
    Włodarczyk M; Sobolewska A; Wójcik B; Loga K; Fichna J; Wiśniewska-Jarosińska M
    World J Gastroenterol; 2014 Jun; 20(22):7019-26. PubMed ID: 24944497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M; Duricova D; Malickova K; Machkova N; Bouzkova E; Hrdlicka L; Komarek A; Lukas M
    J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
    Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
    Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
    Steenholdt C
    Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
    Chauvin A; Le Thuaut A; Belhassan M; Le Baleur Y; Mesli F; Bastuji-Garin S; Delchier JC; Amiot A
    Dig Liver Dis; 2014 Aug; 46(8):695-700. PubMed ID: 24893686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Wittmann T
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):265-9. PubMed ID: 23012667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
    Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Fallingborg J; Christensen LA; Pedersen G; Kjeldsen J; Jacobsen BA; Oxholm AS; Kjellberg J; Bendtzen K; Ainsworth MA
    Gut; 2014 Jun; 63(6):919-27. PubMed ID: 23878167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
    Marits P; Landucci L; Sundin U; Davidsdottir L; Nilsson J; Befrits R; Wikström AC; Eberhardson M
    J Crohns Colitis; 2014 Aug; 8(8):881-9. PubMed ID: 24486178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease.
    Bouchaud G; Mortier E; Flamant M; Barbieux I; Plet A; Galmiche JP; Jacques Y; Bourreille A
    Gastroenterology; 2010 Jun; 138(7):2378-87. PubMed ID: 20188102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different patterns of serum interleukin 10 response to treatment with anti-tumor necrosis factor alpha antibody (infliximab) in Crohn's disease.
    Detková Z; Kupcová V; Príkazská M; Turecký L; Weissová S; Jahnová E
    Physiol Res; 2003; 52(1):95-100. PubMed ID: 12625813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study.
    Armuzzi A; Felice C; Papa A; Marzo M; Pugliese D; Andrisani G; Federico F; De Vitis I; Rapaccini GL; Guidi L
    J Crohns Colitis; 2013 Dec; 7(12):e623-9. PubMed ID: 23810678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
    Noth R; Stüber E; Häsler R; Nikolaus S; Kühbacher T; Hampe J; Bewig B; Schreiber S; Arlt A
    J Crohns Colitis; 2012 May; 6(4):464-9. PubMed ID: 22398062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA; Villela R; Silverberg MS; Greenberg GR
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease.
    Van Assche G; Herrmann KA; Louis E; Everett SM; Colombel JF; Rahier JF; Vanbeckevoort D; Meunier P; Tolan D; Ernst O; Rutgeerts P; Vermeire S; Aerden I; Oortwijn A; Ochsenkühn T
    J Crohns Colitis; 2013 Dec; 7(12):950-7. PubMed ID: 23411006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.